Serum bone Gla protein variations during estrogen and calcium prophylaxis of postmenopausal women.
We have evaluated serum bone Gla protein (BGP) changes in a double-blind study of early postmenopausal women during treatment with estrogen and calcium. To substantiate the changes in bone turnover, serum alkaline phosphatase, 24-hour urinary calcium, and bone mineral content (BMC) have also been measured. Our results indicate that serum BGP is a valuable measurement of bone metabolism.
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000627:therapeutic use* / Q000652:urine; D002135:Calcium-Binding Proteins / Q000097:blood*; D004958:Estradiol / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause; D008903:Minerals / Q000378:metabolism; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D015675:Osteocalcin
D002135:Calcium-Binding Proteins; D004967:Estrogens; D008903:Minerals; D015675:Osteocalcin; D004958:Estradiol; D000077563:Norethindrone Acetate; D000469:Alkaline Phosphatase; D004964:Estriol; D002118:Calcium; D009640:Norethindrone